Fused tricyclic ether carbamates and their use
Tricylic ether carbamates that inhibit HIV proteolytic enzymes and processes for preparing the compounds are describes. Methods of using the disclosed compounds for treating patients infected with HIV are also described.
1. A compound selected from the group consisting of compounds of the formulas
or a pharmaceutically acceptable salt thereof.
2. A compound of the formula
or a pharmaceutically acceptable salt thereof, wherein
X 1 is a bond and R 6 is hydrogen;
X 2 is S(O) 2 , and R 4 is optionally substituted aryl;
R 1 and R 2 are each hydrogen;
R 3 is alkyl which is optionally substituted;
R 5 is optionally substituted arylalkyl;
Z is
wherein * indicates the point of attachment; n is 1 or 2;
W 1 and W 2 are in each instance independently selected from the group consisting of optionally substituted methylene, oxygen, and amino;
W 3 and W 4 are in each instance independently selected from the group consisting of amino, oxygen, alkylene, and heteroalkylene, wherein at least one of W 1 or W 2 is oxygen, and wherein when one of W 1 or W 2 is optionally substituted methylene, at least one of W 3 or W 4 is oxygen, and wherein Z does not include a peroxide bond, a sulfenate bond, or a sulfenamide bond;
X 3 is a bond; and
Y is hydrogen.
3. The compound of claim 2 wherein Z is
wherein * indicates the point of attachment.
4. The compound of claim 2 wherein Z is
wherein W 2 is an oxygen; and * indicates the point of attachment.
5. The compound of claim 2 wherein Z is
and W 2 is an oxygen.
6. The compound of claim 2 wherein R 5 is phenylmethyl.
7. The compound of claim 2 wherein W 3 is oxygen and W 4 is optionally substituted ethylene or propylene.
8. The compound of claim 2 wherein n is 1.
9. The compound of claim 7 wherein W 4 is optionally substituted ethylene.
10. The compound of claim 2 wherein Z is
wherein W 3 is optionally substituted methylene; and W4 is —CH 2 O— or —OCH 2 .
11. The compound of claim 2 wherein W 1 , W 2 , and W 3 are oxygen.
12. A pharmaceutical composition comprising one or more compounds of claim 1 and further comprising one or more carriers, diluents, or excipients, or a combination thereof.
13. A method for treating a patient in need of relief from an HIV infection, the method comprising the step of administering to a patient in need of relief from the HIV infection a therapeutically effective amount of one or more compounds of claim 1 or pharmaceutical composition thereof.
14. The compound of claim 1 of formula
or a pharmaceutically acceptable salt thereof.
15. A method for treating a patient in need of relief from an HIV infection, the method comprising the step of administering to a patient in need of relief from the HIV infection a therapeutically effective amount of the compound of claim 14 or pharmaceutical composition thereof.
16. The compound of claim 1 of formula
or a pharmaceutically acceptable salt thereof.
17. A method for treating a patient in need of relief from an HIV infection, the method comprising the step of administering to a patient in need of relief from the HIV infection a therapeutically effective amount of the compound of claim 16 or pharmaceutical composition thereof.
18. The compound of claim 1 of formula
or a pharmaceutically acceptable salt thereof.
19. A method for treating a patient in need of relief from an HIV infection, the method comprising the step of administering to a patient in need of relief from the HIV infection a therapeutically effective amount of the compound of claim 18 or pharmaceutical composition thereof.
20. A method for treating a patient in need of relief from an HIV infection, the method comprising the step of administering to a patient in need of relief from the HIV infection a therapeutically effective amount of the compound of claim 2 or pharmaceutical composition thereof.